TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest announcement is out from Starpharma Holdings Limited ( (AU:SPL) ).
Starpharma Holdings Limited announced significant progress at its Annual General Meeting, highlighting strategic partnerships with Genentech and Radiopharm Theranostics. These partnerships validate Starpharma’s DEP® platform and open new avenues for innovation and revenue, with the Genentech deal alone potentially bringing in up to USD $564 million in milestone payments. The company is focused on maximizing its DEP® platform, accelerating innovation, and building long-term sustainability, with strategic partnerships playing a crucial role in its growth and market expansion.
The most recent analyst rating on (AU:SPL) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Starpharma Holdings Limited stock, see the AU:SPL Stock Forecast page.
More about Starpharma Holdings Limited
Starpharma Holdings Limited is an innovative biotechnology company specializing in dendrimer technology, which it has been advancing for over two decades. The company focuses on improving health outcomes for patients with significant illnesses, such as cancer, through its unique dendrimer technology. Starpharma’s portfolio includes clinical-stage DEP® assets, preclinical radiopharmaceutical assets, research collaborations, and commercially marketed over-the-counter products.
Average Trading Volume: 1,201,214
Technical Sentiment Signal: Buy
Current Market Cap: A$186.1M
For an in-depth examination of SPL stock, go to TipRanks’ Overview page.